Risk assessment in diabetes management: How do general practitioners estimate risks due to diabetes?

Quality and Safety in Health Care

Volumn 16, Issue 3, 2007, Pages 208-212

  Häussler, Bertram ^a   Fischer, Gisela C ^b   Meyer, Sibylle ^c   Sturm, Diethard ^d  

^a IGES Institut fur Gesundheits und Sozialforschung GmbH   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^c BIS Berliner Inst Sozialforschung   (Germany)

^d Deutscher Hausärzteverband E V   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMPUTATION; ARTICLE; BLINDNESS; CASE REPORT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DECISION MAKING; DIABETES MELLITUS; DISEASE MODEL; FEMALE; GENERAL PRACTITIONER; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LIFE EXPECTANCY; MALE; QUESTIONNAIRE; RISK ASSESSMENT; RISK REDUCTION; STROKE; STRUCTURED INTERVIEW; CLASSIFICATION; CLINICAL COMPETENCE; DECISION SUPPORT SYSTEM; GENERAL PRACTICE; GERMANY; INTERVIEW; MEDICAL AUDIT; MIDDLE AGED; PATHOPHYSIOLOGY; PROBABILITY; PROGNOSIS; STANDARD; TIME;

ADULT; CLINICAL COMPETENCE; DECISION SUPPORT SYSTEMS, CLINICAL; DIABETES COMPLICATIONS; DIABETES MELLITUS; FAMILY PRACTICE; FEMALE; GERMANY; HUMANS; INTERVIEWS; MALE; MEDICAL AUDIT; MIDDLE AGED; PROBABILITY; PROGNOSIS; QUESTIONNAIRES; RISK ASSESSMENT; TIME FACTORS;

EID: 34250867439     PISSN: 14753898     EISSN: None     Source Type: Journal    
DOI: 10.1136/qshc.2006.019539     Document Type: Article

References (20)

1. Young-Hyman D, Herman LJ, Scott DL, et al. Care giver perception of children's obesity-related health risk: a study of African American families. Obes Res 2000;8:241-8.
2. Walker EA, Mertz CK, Kalten MR, et al. Risk perception for developing diabetes - comparative risk judgments of physicians. Diab Care 2003;26:2543-8.
3. Wood DA. European action on secondary prevention by intervention to reduce Events I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001.
4. United Kingdom Prospective Diabetes Study Group (UKPDS 38). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703-13.
5. LaRosa JC, Vupputuri S. Effect of statins on risk of coronary disease: meta-analysis of randomised controlled trials. JAMA 1999;282:2340-6.
6. Harris R, Linn MW. Health beliefs, compliance, and control of diabetes mellitus. South Med J 1985;78:162-6.
7. Mirotznik J, Ginzler E, Zagon G, et al. Using the health belief model to explain clinical appointment-keeping for the management of a chronic disease condition. J Commun Health 1998;23:195-210.
8. Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998;279:1709-14.
9. Weinstein ND: Testing for competing theories of health protective behavior. Health Psychol 1993;12:324-33.
10. Kreuter MW, Strecher VJ. Changing inaccurate perceptions of health risk: results from a randomized trial. Health Psychol 1995;14:56-63.
11. Edwards A, Unigwe S, Elwyn G, et al. Personalised risk communication for informed decision making about entering screening programs. Cochrane Database Syst Rev, 2003,(1):CD001865.
12. Federal Chamber of Physicians. National guideline for diabetes mellitus type 2 (abridged version). Z Arztl Fortbild Qualilatssich 2002;96:1-23.
13. Greve W, Wentura D. Wissenschaftliche Beobachtung. Weinheim: Beltz, Psychologie Verlags Union, 1997.
14. Wirtz M, Caspar F. Beurteilerübereinstimmung und beurteilerreliabilität. Methoden zur bestimmung und verbesserung der zuverlässigkeit von einschätzungen mittels kategoriensystemen und ralingskalen. Göttingen: Hogrefe, 2002.
15. Siegel S, Castellan JN. Nonparametric statistics for the behavioral sciences, 2nd edn. New York: McGraw-Hill, 1998.
16. Häussler B, Berger U, Mast O, et al. Risk and potential risk reduction in diabetes type 2 patients in Germany. Eur J Health Econ 2005;6:152-8.
17. Weber C, Neeser K. Using individualized predictive disease modeling to identify patients with the potential to benefit from a disease management program for diabetes mellitus. Dis Manage 2006;9:242- 56.
18. Neeser K, Lubben G, Siebert U, et al. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. Pharmacoeconomics 2004;22:321-41.
19. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med 2005;37:360-3.
20. Hofer TP, Zemencuk JK, Hayward RA. When there is too much to do: how practicing physicians prioritize among recommended interventions. J Gen Intern Med 2004;19:646-53.